Mylan N.V. announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, a generic version of Celgene’s Vidaza Injection. Mylan received final approval from FDA for its Abbreviated New Drug Application for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British subtypes of myelodysplastic syndrome. jQuery(document).ready(function(){...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
